Advanced Biomed (ADVB) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Advanced Biomed Inc.  (Nasdaq: ADVB)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare


Advanced Biomed's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Advanced Biomed's ROA in the third quarter of 2026?
Advanced Biomed Inc. achieved a return on average assets (ROA) of 49.78 % in its third quarter of 2026, which is below Advanced Biomed's average return on assets, which stands at 56.93%.

Despite the company's net income deteriorating, Advanced Biomed was able to improve its ROA compared to the second quarter of 2025.

However, within the Healthcare sector Advanced Biomed Inc. achieved the highest return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 61, from total ROA ranking in the second quarter of 2025 at 87.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
III. Quarter		 (Dec 31 2025)
II. Quarter		 (Sep 30 2025)
I. Quarter		 (Jun 30 2025)
IV. Quarter		 (Mar 31 2025)
III. Quarter
Y / Y Total Assets Change -9.18 % -0.65 % 44.81 % - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 5 4 -3 -3 -4
Return On Assets (TTM) 49.78 % 40.32 % -31.05 % -32.39 % -54.49 %
ADVB's Total Ranking # 61 # 87 # # #
Total Assets (TTM) in million 11 7 11 14 12
Seq. Total Assets Change 44.29 % -30.94 % -22.11 % 17.02 % 57.84 %
Seq. Net Income Change - - - - -

ADVB's 5 Years Annual ROA >> Back to ADVB Management Effectiveness >> Compare ADVB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry #
Sector #
Overall # 0

Return On Assets Statistics
High Average Low
60.23 %
56.93 %
53.63 %
(Mar 31 2026)   (Dec 31 2025)





Financial Statements
Advanced Biomed's Assets $ 11 million ADVB's Balance sheet
Advanced Biomed's Income $ 0 million Quarterly ADVB's Income Statement
ADVB's Income by Division See ADVB's Income by Division



Annual Return On Assets (Jun 30 2024)
FY 2025
FY
FY
FY
FY
Y / Y Total Assets Change - - - - -
Total Assets in million 7 0 0 0 0
Y / Y Net Income Change - - - - -
Net Income in million -3 0 0 0 0
Annual Return On Assets -37.71 % - - - -

ADVB's 5 Years Annual ROA >> Back to ADVB Management Effectiveness >> Compare ADVB ROA to its Competitors



More Return On Assets Ratios
ADVB's' Return on Assets at Yahoo Finance
Medical Laboratories Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ADVB's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ADVB's Competitors
Subscribers only: Roa for Advanced Biomed's Suppliers
Subscribers only: Return On Assets for ADVB's Customers

You may also want to know
ADVB's Roi ADVB's Inventory Turnover Ratio ADVB's Growth Rates ADVB's Dividend Comparisons
ADVB's Profitability Ratios ADVB's Asset Turnover Ratio ADVB's Dividend Growth
ADVB's Roe ADVB's Valuation Ratios ADVB's Financial Strength Ratios ADVB's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA
Kyntra Bio Inc   120.24 %
Oncotelic Therapeutics Inc   117.43 %
Elutia Inc   110.27 %
Interpace Biosciences Inc   103.25 %
Rigel Pharmaceuticals Inc  99.28 %
Capforce Inc   91.41 %
Quince Therapeutics Inc   90.19 %
Sanuwave Health Inc   74.94 %
Entera Bio Ltd   74.79 %
Pulmatrix Inc   70.49 %
Exelixis Inc   67.15 %
Petros Pharmaceuticals inc   67.03 %
Advanced Biomed Inc.  60.23 %
Fortress Biotech Inc   58.36 %
Q32 Bio Inc   53.33 %
Coherus Oncology inc   50.33 %
Oramed Pharmaceuticals Inc  49.88 %
Aurinia Pharmaceuticals Inc   47.61 %
Zevra Therapeutics Inc   45.60 %
Earth Science Tech Inc   44.55 %
Tg Therapeutics Inc   42.77 %
Lensar Inc   42.26 %
Elite Pharmaceuticals Inc   38.74 %
Dariohealth Corp   37.08 %
Omeros Corporation  34.53 %
Idexx Laboratories Inc  32.56 %
Innoviva Inc   32.36 %
Agenus Inc  30.03 %
Abeona Therapeutics Inc   29.55 %
Escalon Medical Corp   29.20 %

Date modified: 2026-09-04T09:58:57+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.